December 13, 2019
Rose
In August, the maker of the treatment, Sarepta, said the FDA rejected the drug over the risk of infections seen in animal experiments. The new approval announcement made no mention of the prior rejection.
from Kaiser Health News https://ift.tt/2EqDzil
December 13, 2019
Rose
Health News, Kaiser Health News
No comments
Related Posts:
Geographical Disparities Created By Medicaid Restrictions Has Some People Crossing State Lines To Seek Care- Massachusetts Says It’s Worth It To Pay For Uber-Pricey Drugs … But Only If They Work
- House Ways And Means Expected To Drop Benchmark Payments That Hospitals Hate In New Surprise Billing Plan
- More Than 200 Health Professionals Speak Out About Wave Of State-Level Bills Aimed At Care For Transgender Youth
- Federal Officials Seek Information On Coverage ‘Guardrails’ Georgia Plans To Put In Place With Health Care Revamp
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment